Literature DB >> 21642996

What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?

Mikio Namiki1, Hiroyuki Konaka.   

Abstract

Entities:  

Year:  2011        PMID： 21642996      PMCID： PMC3739621          DOI： 10.1038/aja.2011.74

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  9 in total

Review 1.  Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer.

Authors:  Nathan Bittner; Gregory S Merrick; Kent E Wallner; Wayne M Butler
Journal:  Oncology (Williston Park)       Date:  2008-08       Impact factor: 2.990

2.  Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy.

Authors:  A L Zietman; W U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

3.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este
Journal:  Lancet Oncol       Date:  2011-05       Impact factor: 41.316

Review 4.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.

Authors:  S Nag; D Beyer; J Friedland; P Grimm; R Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

5.  Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.

Authors:  Patrick J Bastian; Mark L Gonzalgo; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Joseph C Presti; Leslie A Mangold; Elizabeth Humphreys; Jonathan I Epstein; Alan W Partin; Stephen J Freedland
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

6.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

7.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Authors:  Eric M Horwitz; Kyounghwa Bae; Gerald E Hanks; Arthur Porter; David J Grignon; Harmar D Brereton; Varagur Venkatesan; Colleen A Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

8.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

9.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
  9 in total
  3 in total

1.  Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer.

Authors:  Xu-Dong Yao; Xiao-Jun Liu; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

2.  Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy.

Authors:  Wei Ouyang; Yucong Zhang; Gongwei Long; Guoliang Sun; Man Liu; Fan Li; Chunguang Yang; Xing Zeng; Jun Yang; Xiao Yu; Zhihua Wang; Zheng Liu; Wei Guan; Zhiquan Hu; Shaogang Wang; Xiaming Liu; Heng Li; Hua Xu; Zhangqun Ye
Journal:  Biomark Res       Date:  2021-03-31

3.  Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005.

Authors:  Kun Chang; Xiao-Jian Qin; Hai-Liang Zhang; Bo Dai; Yao Zhu; Guo-Hai Shi; Yi-Jun Shen; Yi-Ying Zhu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.